Eva H.
- Country
- Hungary
- Department
- Gyermekgyogyaszati Klinika Tuzolto utcai reszleg
Research Overview
- Safety Follow-up Study to Assess the Safety of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta
- A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus (MK-8835-059/B1521066)
- Evaluation of Romosozumab Versus Bisphosphonates in Pediatric Osteogenesis Imperfecta: A Phase 3, Open-Label, Multicenter, Randomized Study
Data & Insights
Has run more than one trial at 14 of 36 partner sites.
Specializations
Diabetes Management
This investigator specializes in studying therapeutic approaches for Type 2 Diabetes Mellitus, with particular emphasis on innovative treatment strategies for pediatric populations.
- Glycemic Control Assessment
- Pediatric Diabetes Care
- SGLT2 Inhibitor Research
The research focus includes evaluating therapeutic interventions that target hemoglobin A1C levels in young patients with diabetes.
Pediatric Therapeutics
The investigator conducts research in pediatric medicine with a focus on metabolic disorders and their treatment approaches.
- Long-term Safety Monitoring
- Treatment Tolerability
- Pediatric Drug Development
Areas of interest include the evaluation of therapeutic safety profiles in pediatric populations over extended treatment periods.
Clinical Assessment
The investigator specializes in comparative therapeutic assessment methodologies within the context of metabolic disease management.
- Treatment Efficacy Evaluation
- Metabolic Response Assessment
- Clinical Outcomes Analysis
Research activities focus on evaluating therapeutic interventions through systematic clinical assessment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.